173 related articles for article (PubMed ID: 36697561)
1. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors.
Qu L; Chen X; Wei H; Guo M; Dai S; Jiang L; Li J; Yue S; Chen Z; Chen Y
Commun Chem; 2022 Jan; 5(1):5. PubMed ID: 36697561
[TBL] [Abstract][Full Text] [Related]
2. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
3. The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance.
Venetsanakos E; Brameld KA; Phan VT; Verner E; Owens TD; Xing Y; Tam D; LaStant J; Leung K; Karr DE; Hill RJ; Gerritsen ME; Goldstein DM; Funk JO; Bradshaw JM
Mol Cancer Ther; 2017 Dec; 16(12):2668-2676. PubMed ID: 28978721
[TBL] [Abstract][Full Text] [Related]
4. Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R.
Lin Q; Dai S; Qu L; Lin H; Guo M; Wei H; Chen Y; Chen X
Commun Chem; 2024 Jan; 7(1):3. PubMed ID: 38172256
[TBL] [Abstract][Full Text] [Related]
5. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
6. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
Deng W; Chen X; Liang H; Song X; Xiang S; Guo J; Tu Z; Zhou Y; Chen Y; Lu X
Eur J Med Chem; 2024 Jun; 275():116558. PubMed ID: 38870833
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use.
Ito S; Otsuki S; Ohsawa H; Hirano A; Kazuno H; Yamashita S; Egami K; Shibata Y; Yamamiya I; Yamashita F; Kodama Y; Funabashi K; Kazuno H; Komori T; Suzuki S; Sootome H; Hirai H; Sagara T
ACS Med Chem Lett; 2023 Apr; 14(4):396-404. PubMed ID: 37077386
[TBL] [Abstract][Full Text] [Related]
9. Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455.
Wu D; Guo M; Philips MA; Qu L; Jiang L; Li J; Chen X; Chen Z; Chen L; Chen Y
PLoS One; 2016; 11(9):e0162491. PubMed ID: 27618313
[TBL] [Abstract][Full Text] [Related]
10. DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.
Huang Z; Tan L; Wang H; Liu Y; Blais S; Deng J; Neubert TA; Gray NS; Li X; Mohammadi M
ACS Chem Biol; 2015 Jan; 10(1):299-309. PubMed ID: 25317566
[TBL] [Abstract][Full Text] [Related]
11. Computational Biophysical Characterization of the Effect of Gatekeeper Mutations on the Binding of Ponatinib to the FGFR Kinase.
Mahapatra S; Kar P
Arch Biochem Biophys; 2024 Jun; ():110070. PubMed ID: 38909834
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of a dual-warhead covalent inhibitor of FGFR4.
Chen X; Li H; Lin Q; Dai S; Yue S; Qu L; Li M; Guo M; Wei H; Li J; Jiang L; Xu G; Chen Y
Commun Chem; 2022 Mar; 5(1):36. PubMed ID: 36697897
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q; Chen X; Qu L; Guo M; Wei H; Dai S; Jiang L; Chen Y
Commun Chem; 2022 Aug; 5(1):100. PubMed ID: 36698015
[TBL] [Abstract][Full Text] [Related]
14. Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S
Schwarz M; Kurkunov M; Wittlinger F; Rudalska R; Wang G; Schwalm MP; Rasch A; Wagner B; Laufer SA; Knapp S; Dauch D; Gehringer M
J Med Chem; 2024 Apr; 67(8):6549-6569. PubMed ID: 38604131
[TBL] [Abstract][Full Text] [Related]
15. A structure-guided approach to creating covalent FGFR inhibitors.
Zhou W; Hur W; McDermott U; Dutt A; Xian W; Ficarro SB; Zhang J; Sharma SV; Brugge J; Meyerson M; Settleman J; Gray NS
Chem Biol; 2010 Mar; 17(3):285-95. PubMed ID: 20338520
[TBL] [Abstract][Full Text] [Related]
16. Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo M; Dai S; Wu D; Duan Y; Li J; Qu L; Jiang L; Chen Z; Chen X; Chen Y
Bioorg Med Chem Lett; 2021 Feb; 34():127757. PubMed ID: 33359446
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X
J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262
[TBL] [Abstract][Full Text] [Related]
18. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure.
Kalyukina M; Yosaatmadja Y; Middleditch MJ; Patterson AV; Smaill JB; Squire CJ
ChemMedChem; 2019 Feb; 14(4):494-500. PubMed ID: 30600916
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.
Brameld KA; Owens TD; Verner E; Venetsanakos E; Bradshaw JM; Phan VT; Tam D; Leung K; Shu J; LaStant J; Loughhead DG; Ton T; Karr DE; Gerritsen ME; Goldstein DM; Funk JO
J Med Chem; 2017 Aug; 60(15):6516-6527. PubMed ID: 28665128
[TBL] [Abstract][Full Text] [Related]
20. Structural study of ponatinib in inhibiting SRC kinase.
Guo M; Duan Y; Dai S; Li J; Chen X; Qu L; Chen Z; Wei H; Jiang L; Chen Y
Biochem Biophys Res Commun; 2022 Apr; 598():15-19. PubMed ID: 35151199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
